Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy

Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy

Among respiratory infections, tuberculosis was the second deadliest infectious disease in 2020 behind COVID-19. Inhalable nanocarriers offer the possibility of actively targeting anti-tuberculosis drugs to the lungs, especially to alveolar macrophages (cellular reservoirs of the <i>Mycobacteri...

Full description

Bibliographic Details
Main Authors: Juan M. Galdopórpora, Camila Martinena, Ezequiel Bernabeu, Jennifer Riedel, Lucia Palmas, Ines Castangia, Maria Letizia Manca, Mariana Garcés, Juan Lázaro-Martinez, Maria Jimena Salgueiro, Pablo Evelson, Nancy Liliana Tateosian, Diego Andres Chiappetta, Marcela Analia Moretton
Format: Article
Language:English
Published: MDPI AG 2022-04-01
Series:Pharmaceutics
Subjects:
polymeric micelles
Soluplus<sup>®</sup>
rifampicin
curcumin
tuberculosis
inhalable nanoformulation
Online Access:https://www.mdpi.com/1999-4923/14/5/959

Internet

https://www.mdpi.com/1999-4923/14/5/959

Similar Items